Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients

NCT05686759 is registered in ClinicalTrials.gov with GC Biopharma Corp as lead sponsor.

NCT NCT05686759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05686759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients
Lead sponsor
GC Biopharma Corp
Phase
Phase 3
Overall status
Recruiting
Start date
April 13, 2023
Completion date
June 30, 2026
Enrollment
105 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b